Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children.
Activins
/ blood
Adolescent
Biomarkers
/ blood
Broadly Neutralizing Antibodies
/ immunology
Chemokine CXCL13
/ blood
Child
Cohort Studies
Disease Progression
Germinal Center
/ immunology
HIV Antibodies
/ immunology
HIV Infections
/ blood
HIV-1
/ immunology
Humans
Interleukin-5
/ blood
Neutralization Tests
T-Lymphocytes, Helper-Inducer
/ immunology
Viral Load
Activin A
CXCL13
HIV neutralization breadth
IL-5
T-follicular helper cells (Tfh)
broadly neutralizing antibodies (bnAbs)
pediatric HIV
plasma markers
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
03
2019
accepted:
14
06
2019
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
16
7
2020
Statut:
epublish
Résumé
Children may be the optimal target for HIV vaccine development as they generate substantially more frequent and more potent broadly HIV neutralizing antibodies (bnAbs) than adults. Development of a biomarker that correlates with neutralization breadth in this group could function as a powerful tool to facilitate the development of an HIV vaccine. Previously, we observed that this preferential ability in HIV-infected children over adults to generate bnAbs is associated with an enrichment of circulating follicular helper T-cells (T
Identifiants
pubmed: 31333650
doi: 10.3389/fimmu.2019.01497
pmc: PMC6615198
doi:
Substances chimiques
Biomarkers
0
Broadly Neutralizing Antibodies
0
CXCL13 protein, human
0
Chemokine CXCL13
0
HIV Antibodies
0
IL5 protein, human
0
Interleukin-5
0
activin A
0
Activins
104625-48-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1497Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI133673
Pays : United States
Références
J Exp Med. 2000 Dec 4;192(11):1553-62
pubmed: 11104798
Eur Cytokine Netw. 2001 Apr-Jun;12(2):253-9
pubmed: 11399513
J Interferon Cytokine Res. 2005 Nov;25(11):702-6
pubmed: 16318584
Eur J Immunol. 2008 Apr;38(4):995-1000
pubmed: 18383036
Blood. 2008 Sep 1;112(5):1620-7
pubmed: 18550853
Br J Cancer. 2008 Sep 16;99(6):930-8
pubmed: 18781150
J Clin Immunol. 2010 Jan;30(1):45-52
pubmed: 19774453
J Rheumatol. 2010 Jan;37(1):45-52
pubmed: 19955043
J Infect Dis. 2010 Apr 1;201(7):981-3
pubmed: 20170372
Annu Rev Immunol. 2011;29:621-63
pubmed: 21314428
J Immunol. 1990 Oct 15;145(8):2440-7
pubmed: 2212647
J Immunol. 2012 Jan 15;188(2):703-13
pubmed: 22174445
Blood. 2012 May 10;119(19):4441-50
pubmed: 22310911
Nat Med. 2013 Feb;19(2):143-9
pubmed: 23389614
Front Immunol. 2013 Aug 02;4:208
pubmed: 23935597
Immunity. 2013 Oct 17;39(4):758-69
pubmed: 24035365
Nat Med. 2014 Jun;20(6):655-8
pubmed: 24859529
J Virol. 2014 Nov;88(22):13310-21
pubmed: 25210168
J Allergy Clin Immunol. 2015 Mar;135(3):626-35
pubmed: 25528359
Nat Rev Immunol. 2015 Mar;15(3):185-9
pubmed: 25677493
Clin Vaccine Immunol. 2015 Dec 09;23(2):84-94
pubmed: 26656117
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7
pubmed: 26908875
Nat Immunol. 2016 Aug;17(8):976-84
pubmed: 27376469
Sci Transl Med. 2016 Sep 28;8(358):358ra125
pubmed: 27683550
Cell Rep. 2016 Nov 22;17(9):2195-2209
pubmed: 27880897
J Int AIDS Soc. 2016 Dec 09;19(1):21136
pubmed: 27938646
Clin Infect Dis. 2017 Apr 15;64(8):1098-1104
pubmed: 28158448
Immunity. 2017 Mar 21;46(3):350-363
pubmed: 28329702
Sci Rep. 2017 Aug 21;7(1):8956
pubmed: 28827754
Front Immunol. 2017 Sep 08;8:1104
pubmed: 28943879
J Virol. 2017 Dec 14;92(1):
pubmed: 29021402
Front Immunol. 2018 Sep 12;9:1975
pubmed: 30258437
Front Immunol. 2019 Feb 21;10:289
pubmed: 30846990
Vaccine. 2019 Apr 17;37(17):2348-2355
pubmed: 30914222
Immunol Rev. 1988 Feb;102:107-35
pubmed: 3284812
J Exp Med. 1993 Nov 1;178(5):1577-86
pubmed: 8228808